09:09 AM EST, 12/29/2025 (MT Newswires) -- (Updates with Novo Nordisk ( NVO ) comment in the fourth paragraph.)

Novo Nordisk ( NVO ) has cut the listing prices of its obesity drug Wegovy by about half in some Chinese provinces, Bloomberg reported Monday, citing Chinese media outlet Yicai.

The report said the list prices for the two highest dosages were reduced to 987.48 yuan ($141) and 1,284.36 yuan respectively, citing drug-procurement documents for southwestern Chinese provinces Yunnan and Sichuan.

Novo Nordisk's ( NVO ) patent on semaglutide, the active ingredient in both Wegovy and Ozempic, is set to expire in China in March, paving the way for local companies to launch cheaper generics, according to Bloomberg.

"We can confirm that we are adjusting our prices of Wegovy in China," a Novo Nordisk ( NVO ) representative said in an emailed statement to MT Newswires. "We believe this pricing adjustment in China will further help alleviate the treatment burden for patients and improve their quality of life."

Bloomberg said prices on the online marketplace operated by Chinese e-commerce platform JD.com were also lowered.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)